Abbott agrees to pay about $385 million over alleged WIC and Medicaid product-quality misrepresentations
Oct 11, 2026 edition · GC-2026-0105 · Published 2026-10-11 · Version 4 · Settled
Abbott’s roughly $385 million settlement resolves disputed government-payment claims tied to formula manufacturing and quality representations. The agreement separates federal, state Medicaid and Massachusetts WIC amounts, conditions releases on payment, and reserves several other categories of claims.
What happened
The Abbott settlement concerns allegations about powdered infant formula and nutritional products manufactured at its Sturgis, Michigan, and Casa Grande, Arizona, facilities. The agreement defines the covered period as January 1, 2018, through December 31, 2022. Government parties contend that Abbott failed to meet applicable manufacturing requirements and made inaccurate representations connected with purchases funded through WIC and Medicaid. Abbott denies the allegations. The agreement resolves specified civil claims arising from that covered conduct; it is not an admission that the disputed allegations are true.
The required settlement amount is $384,999,040.12 plus interest, divided among the federal government, participating state Medicaid programs and Massachusetts WIC. The federal release is conditioned on receipt of the federal payment, so an executed agreement alone does not establish completed payment or collection. Reserved claims include criminal liability, specified administrative remedies, other conduct and personal-injury or property-damage claims. The agreement also treats specified investigation, defense, corrective-action and settlement costs as unallowable government-program costs and requires separate accounting. These limits matter when evaluating what the resolution settles and how related costs may enter government contracts or Medicaid cost reporting; later payment performance was not independently established for this edition.
Scope and timing
- Authority status
- Settled
- Applicability
- Operationally relevant
- Audience
- Health systems, Provider networks
- Jurisdiction
- Federal, California
Why it matters
The settlement connects product-quality compliance, government-program eligibility representations, and False Claims Act exposure. Medicaid and WIC suppliers need evidence that regulatory and contractual quality claims remain accurate throughout production.
Recommended action
Government-program suppliers should map product-quality representations to manufacturing evidence, confirm escalation of deviations and recalls, and test whether invoices or rebate submissions continue after a quality representation becomes inaccurate.
Case details
- agencies
- U.S. Department of Justice, U.S. Department of Agriculture, HHS Office of Inspector General, State Medicaid programs
- entities
- Abbott Laboratories
- action Type
- Settlement
- event Date
- 2026-09-14
- alleged Conduct
- Alleged failure to manufacture covered formula and nutritional products in compliance with requirements and alleged misrepresentations to WIC and Medicaid programs. Abbott denied the allegations.
- resolution
- Abbott agreed to pay $384,999,040.12 plus interest; actual payment receipt is not established by this agreement alone.
Operational lessons
- Product-quality deviations can create payment-integrity exposure.
- Program eligibility representations need continuing support.
- Unallowable settlement costs must be separated from government-program claims and cost reporting.
Sources
- Abbott False Claims Act Settlement AgreementOfficial · U.S. Department of Justice · 2026-09-14 · Source review 2026-10-11
Complete edition and supplemental material
This finding in the complete approved report →Regulatory horizons, CIA trends and implementation trackers remain in the full report.
Read the entire Enforcement Briefing report →